# Successful Treatment of a Case of Crescentic Glomerulonephritis in a Patient with Primary Peritoneal Carcinoma: A case report

## TL;DR

A patient with peritoneal cancer and severe kidney disease improved significantly after treatment with rituximab and steroids.

## Contribution

This case report documents a rare instance of crescentic glomerulonephritis alongside peritoneal cancer and its successful treatment.

## Key findings

- The patient's kidney function improved significantly after receiving rituximab and corticosteroids.
- Proteinuria resolved within 10 weeks, and eGFR increased from 13 to over 60 mL/min.
- Chemotherapy normalized the patient's CA-125 levels within three months.

## Abstract

Crescentic glomerulonephritis has been associated with several solid tumour malignancies. Only a few cases of nephropathy have been reported in association with tubo-ovarian/peritoneal malignancies. We report a 55-year-old female patient who presented to a tertiary care centre, Muscat, Oman, in 2022. She developed combined immune complex-mediated glomerulonephritis and pauci-immune necrotising crescentic vasculitis simultaneously with the diagnosis of tubo-ovarian/peritoneal cancer. The baseline estimated glomerular filtration rate (eGFR) was 13 mL/min. The patient received two doses of rituximab and three doses of pulse corticosteroids, leading to significant improvement in renal function and the disappearance of her proteinuria. The eGFR improved to >60mL/min; her proteinuria gradually resolved after 10 weeks of treatment. She was then given a combination chemotherapy treatment for tubo-ovarian/peritoneal cancer leading to a normalisation of her CA-125 after three months of therapy.